Marvel's superheroes have returned to Chinese cinemas with the "Black Panther: Wakanda Forever" movie on Tuesday after a 4-year absence.
The last Marvel movie to be released in China was "Spider-Man: Far from Home" in July 2019.
The Communist Party's propaganda arm, the China Film Administration, has not explained why Marvel movies aren't playing in theaters.
The apparent Marvel films ban ended just as China loosened its zero-COVID policies that disrupted its entertainment industry for years.
Blockbuster Marvel movies have made billions of dollars worldwide, and their return to one of the biggest movie markets might bring in hundreds of millions of dollars for Marvel owner Disney.
The first Black Panther movie brought in $105 million In Chinese theaters.
The next Marvel film to be shown in Chinese theaters is "Ant-Man and the Wasp: Quantumania," to be released on February 17.


Disaster or digital spectacle? The dangers of using floods to create social media content
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Stuck in a creativity slump at work? Here are some surprising ways to get your spark back
Why financial hardship is more likely if you’re disabled or sick
Oil Prices Slip as U.S.-Iran Talks Ease Middle East Tensions
Anta Sports Expands Global Footprint With Strategic Puma Stake
Australian Household Spending Dips in December as RBA Tightens Policy
Samsung Electronics Shares Jump on HBM4 Mass Production Report
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Glastonbury is as popular than ever, but complaints about the lineup reveal its generational challenge
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Every generation thinks they had it the toughest, but for Gen Z, they’re probably right
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 



